![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2023/02/15/2608809/0/en/RadioMedix-Inc-Announces-the-Acquisition-of-its-225Ac-PSMA-I-T-program-a-Targeted-Alpha-Therapy-TAT-for-Metastatic-Castration-Resistant-Prostate-Cancer-by-Fusion-Pharmaceuticals-In.html
https://www.globenewswire.com/news-release/2022/11/15/2555865/0/en/RadioMedix-and-Vect-Horus-announce-first-dosing-of-Glioblastoma-Multiforme-and-Pancreatic-ductal-adenocarcinoma-patients-with-68Ga-RMX-VH.html
https://www.globenewswire.com/news-release/2022/10/07/2530586/0/en/RadioMedix-announces-a-40-million-Series-A-financing-for-the-advancement-of-novel-Targeted-Alpha-Therapy-platform-and-diagnostic-companion-radiopharmaceuticals-to-address-unmet-nee.html
https://www.globenewswire.com/news-release/2022/01/03/2360157/0/en/Radiomedix-and-Orano-Med-Announce-the-Initiation-of-the-Phase-II-Multi-Center-Clinical-Trial-of-Alphamedix-for-Targeted-Alpha-Emitter-Therapy-of-Neuroendocrine-Cancers.html